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MO1
IMPACT OF INCLUDING CARDIOVASCULAR AND RESPIRATORY 
OUTCOMES ON ESTIMATES OF CLINICAL AND ECONOMIC BENEFITS
OF INFLUENZA VACCINATION IN THE U.S. ELDERLY POPULATION
Gao X1, Snedecor SJ1, Ethgen O2, Botteman MF1
1PharMerit North America LLC, Bethesda, MD, USA, 2GSK Biologicals, Rixensart, Belgium
OBJECTIVES: Inﬂ uenza virus activity increases hospitalizations for a broad range of 
cardiopulmonary diagnoses, including pneumonia and inﬂ uenza (P&I). However, only
a few economic studies have even partially incorporated broader respiratory (including
P&I) and cardiovascular outcomes (R&C) in assessing vaccination effects. We devel-
oped a conceptual model that assessed the costs and beneﬁ ts of vaccinating elderly
individuals from a US societal perspective based on 2 different outcomes (P&I only
vs. R&C). METHODS: A literature-based decision model was used to estimate the 
short- and long-term costs and quality-adjusted life expectancy (QALE) associated
with annual inﬂ uenza vaccination for the elderly population (aged q 65 years, N 
37,888,000). One version of the model included P&I outcomes only whereas the other 
version included the broader inﬂ uenza-related R&C outcomes. The reduction rate
of inﬂ uenza due to vaccination was 30% and applied to the probability of seeking 
medical attention, antivirals and antibiotics utilization, and indirect costs. The reduc-
tion in hospitalization due to inﬂ uenza was calibrated to reﬂ ect recent epidemiologic 
estimates. RESULTS: When only P&I were modeled, the number of hospitalizations
was 63,000 and 88,000 with and without vaccination, respectively. The QALE per
person was 7.7514 versus 7.7509 years; and the average cost per person was $118 
versus $121, respectively. When R&C were modeled, the number of hospitalizations
increased to 180,000 and 239,000; the QALE per person decreased to 7.7392 and
7.7355; and the average cost increased to $325 and $388, respectively, with and 
without vaccination. The inclusion of all R&C outcomes improved the estimated 
vaccination beneﬁ ts, with more hospitalizations avoided (34,000), QALE gained
(123,000 QALYs), and cost savings ($2 billion). Results were similar in sensitivity
analyses. CONCLUSIONS: Excluding R&C outcomes considerably underestimates 
the burden of inﬂ uenza and the economic beneﬁ ts of inﬂ uenza vaccination. Future
economic assessments of inﬂ uenza vaccination strategies should include all R&C 
outcomes.
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A SYSTEMATIC EVALUATION OF EMPIRICAL BAYES METHODS 
UNDER TIME CENSORED CONDITIONS
Murray JF1, Fryback DG2
1Eli Lilly and Company, Indianapolis, IN, USA, 2University of Wisconsin – Madison, Madison, 
WI, USA
OBJECTIVES: Quality assurance must identify problems among a group of providers 
using sparse observations within some providers, posing problems of estimation. We 
compare Empirical Bayes (EB) methods for estimating means and conﬁ dence intervals
to classical statistical estimates when time frames are censored. METHODS: Retrospec-
tive data on four measures with various units of analysis were selected: (1) quality of 
care for psychiatric emergencies by physicians, (2) cesarean sections rates in hospitals,
(3) LOS for ﬁ ve DRGs in hospitals, and (4) “cost” for ﬁ ve DRGs by hospital. Data 
was available for overall time frames of one to two years. Individual unit of analysis 
results from the overall time frame were assumed as the “best” estimate of true per-
formance. Data sets were subset into shorter time periods (i.e., months or quarters).
EB priors were estimated by averaging results across units of analysis within each cen-
sored time frame. Priors were combined with the observed data to form posterior esti-
mates for individuals; bootstrap methods were used to estimate Bayesian conﬁ dence 
intervals. Bayesian and Classical estimates of means and conﬁ dence intervals were 
compared within and across time periods by units of analysis on four measures of 
“goodness”: (1) Absolute difference between the “true” mean and the classical and EB
estimates, (2) frequency of the EB mean being closest to the “true” mean, (3) average 
widths of the EB and classical intervals, and the actual probability coverage of the
estimated intervals. RESULTS: EB methods were consistently closer in absolute differ-
ence and by frequency to the “true” mean. EB conﬁ dence intervals were consistently 
narrower giving less uncertainty about the location of the true mean while maintaining 
the expected probability coverage. CONCLUSION: Empirical Bayes methods can 
mitigate the adverse effect of sparse samples at the provider level compared to classical 
estimation for quality assurance when limited time constrains observations.
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INTEGRATING INDIVIDUAL PATIENT LEVEL RCT DATA WITH A
COMPREHENSIVE DECISION ANALYTIC COST EFFECTIVENESS MODEL
Manca A1, Saramago P1, Henriksson M2
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OBJECTIVES: Randomised controlled trials (RCTs) are the gold standard for demon-
strating the efﬁ cacy of medical interventions. However, RCTs may be neither sufﬁ cient
nor the most efﬁ cient vehicle to generate cost effectiveness (CE) evidence to inform 
health care resource allocation decisions. RCT evidence may a) not be directly relevant 
to a given jurisdiction; b) exclude relevant treatment strategies; c) be too short in follow 
up. Comprehensive decision-analytic models (CDAMs) can help address the above 
challenges. These models are typically populated using summary measures, and often 
require strong distributional assumptions concerning their input parameters. We 
extend the use of CDAM, to accommodate and exploit the wealth of information 
contained in an individual patient-level dataset (IPD). METHODS: Using the UK 
RITA-3 trial, we show how to conduct a Bayesian analysis of IPD with the aim to a)
estimate input parameters to populate a CDAM, and b) inform probabilistic sensitivity 
analysis (PSA) to evaluate the decision problem. The proposed framework allows
simultaneous estimation of a system of risk equations for speciﬁ c events of interest, 
estimation of costs and quality of life implications related to the occurrence of these 
events, and PSA into a single CE model. Results are compared and contrasted with 
those from a standard two-stage approach, i.e. estimation of parameters through clas-
sical statistical inference, followed by PSA in a spreadsheet. RESULTS: Using IPD
within the proposed analytical framework produced more accurate estimates than the 
standard two-stage approach in terms of posterior distributions of the incremental costs
and QALYs. This resulted in a reduced decision uncertainty, as represented by the CE 
acceptability curve. CONCLUSIONS: CDAM based on IPD looks more promising and 
appropriate from the methodological point of view than standard (two-stage) model-
ling methods. This general analytical framework can be further extended to facilitate 
statistical evidence synthesis in the presence of multiple data sources.
MO4
RE-EXAMINING THE SPECIFICATION OF REGRESSION MODELS OF
MULTINOMIAL RESPONSES: AN APPLICATION TO PREDICTING POST-
STROKE DISCHARGE DISPOSITION
Bergtold J1, Onukwugha E2
1Kansas State University, Manhattan, KS, USA, 2University of Maryland School of Pharmacy, 
Baltimore, MD, USA
Current approaches to specifying multinomial logistic models (MLM) have not high-
lighted the statistical adequacy of the model speciﬁ cation or the implications of pos-
sible misspeciﬁ cation due to patterns common to observational data. The probabilistic 
reduction (PR) approach provides a framework to guide model speciﬁ cation when 
using observational data. OBJECTIVE: The objective of this study is to examine the
speciﬁ cation of MLM using the PR approach, with an application to identifying pre-
dictors of hospital discharge disposition among stroke patients. METHODS: Within 
the PR approach, the index function associated with the choice probability is function-
ally related to the inverse conditional distribution. Operationalization of the index 
function leads to the consideration of nonlinear terms and interacted terms, based on 
the inverse conditional distribution and the existence of dependence across model 
covariates. To illustrate the methodology, an empirical application examined predic-
tors of hospital discharge disposition among live discharges of adult stroke patients 
in Maryland using a population-based discharge dataset (N  79,561). Categories of 
discharge disposition included home, home health care, rehabilitation, nursing home, 
discharges against medical advice, and ‘all other’. Covariates controlled for patient
demographic and clinical characteristics. A traditional MLM speciﬁ cation and a model 
speciﬁ ed following the PR approach were estimated and compared. RESULTS: Results 
based on the information criteria (traditional speciﬁ cation: AIC  194377.1 and AICC:
194377.2; PR speciﬁ cation: AIC  192705.5 and AICC: 192738.1) estimates and the 
likelihood ratio test (p-value  0.000) showed that the PR approach provides a better 
ﬁ t and that the traditional speciﬁ cation of the model is misspeciﬁ ed. We also estimate
marginal effects of the explanatory variables on the probability of each discharge 
category. CONCLUSION: The novel ﬁ nding is that the PR approach can be used to 
specify discrete choice models that provide a better ﬁ t to observational data, compared 
to models speciﬁ ed using more common approaches.
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COST–EFFECTIVENESS OF DISEASE–MODIFYING THERAPY FOR 
MULTIPLE SCLEROSIS: A POPULATION–BASED EVALUATION
Noyes K1, Bajorska A1, Chappel AR2, Schwid S1, Mehta LR2, Holloway R1, Dick A3
1University of Rochester School of Medicine, Rochester, NY, USA, 2University of Rochester, 
Rochester, NY, USA, 3The RAND Corporation, Pittsburgh, PA, USA
OBJECTIVES: Costly disease modifying therapies (DMTs: interferon beta-1a and 
beta-1b and glatiramer acetate) were introduced in the 1990s to reduce the frequency 
of relapses and to slow disease progression in patients with multiple sclerosis (MS).
At the same time, these therapies are characterized by uncomfortable side effects and 
high costs. This study examines data from a 2000–2005 population-based survey of 
MS patients from the Sonya Slifka Study to evaluate the cost-effectiveness (CE) of 
DMTs in the US compared to no DMT. METHODS: We generated 10-year disease 
progression paths using ﬁ rst-order Markov models to estimate transitional probabili-
ties and logistic models to estimate relapse rates based on published estimates of DMT 
treatment effects. To estimate costs, we used Medicare rates for reported utilization 
events. Outcomes were measured as gains in quality-adjusted life years (QALY) and
relapse-free years, differences in the number of disease progressions (as measured by 
disability status), and gains in years spent in lower disability states. Monte Carlo (n 
 50) simulations, resampling (n  250) methods, and sensitivity analyses were con-
ducted to evaluate uncertainty. RESULTS: Using DMT for 10 years resulted in signiﬁ -
cant health gains. The choice of the optimal therapy depends on the outcome, with 
interferons generating the highest QALY gain (0.187 QALY), fewer disease progres-
sions (by 0.91), fewer years spent in higher disability states (by 0.81 year), and leading 
to more relapse-free years (by 1.12 year) compared to glatiramer or no DMT. The 
CE of all DMTs exceeded $1,000,000/QALY, with glatiramer being the most cost-
ineffective ($5,209,524/QALY). As the cost of DMT decreases, DMTs become more 
